分化型甲状腺癌术前血清CCL11 CCL18水平与临床病理特征及复发的关系及预测价值研究

doi:10.3969/j.issn.1006-6233.2025.02.018

摘要
图/表
参考文献
相关文章 (15)

全文: PDF (1256 KB) HTML (1 KB)
输出: BibTeX | EndNote (RIS)

摘要 目的: 分析分化型甲状腺癌术前血清CC修饰趋化因子11(CCL11)、CC修饰趋化因子18(CCL18)水平与临床病理特征及复发的关系研究,并分析CCL11、CCL18水平对复发的预测价值。方法: 选取2020年3月至2023年3月于本院接受治疗的151例分化型甲状腺癌患者为研究对象,术前均测定其血清CCL11、CCL18水平,依据其术后1年是否复发分为复发组(n=35)和未复发组(n=116)。对比不同临床病理特征患者术前血清CCL11、CCL18水平,以受试者特征工作曲线(ROC)分析术前血清CCL11、CCL18水平对术后复发的预测价值。结果: 复发组的术前血清CCL11、CCL18水平高于未复发组(P<0.05)。术前血清CCL11、CCL18水平与淋巴结转移、浸润深度和TNM分期有关(P<0.05),与病灶数量、肿物内部微钙化等临床病理特征无关(P>0.05)。ROC曲线显示,术前血清CCL11、CCL18单独及联合预测分化型甲状腺癌术后复发的曲线下面积(AUC)分别为0.612、0.725、0.892,灵敏度分别为71.43%、77.14%、80.00%,特异性分别为55.17%、62.21%、90.52%,联合预测效能优于各指标单独预测(P<0.05)。结论: 术前血清CCL11、CCL18水平与分化型甲状腺癌患者的临床病理特征及复发密切相关,通过测定术前血清CCL11、CCL18水平,可为患者的术后复发提供一定的预测价值。

	服务

	把本文推荐给朋友
	加入我的书架
	加入引用管理器
	E-mail Alert
	RSS
	作者相关文章
	李栋栋
	郑晨
	郑二良

关键词 ：分化型甲状腺癌, CC修饰趋化因子11, CC修饰趋化因子18, 临床病理特征, 复发, 相关性, 预测价值

Abstract：Objective: To analyze the relationship between the baseline level of serum C-C motif chemokine ligand 11 (CCL11) and C-C motif chemokine ligand 18 (CCL18) with clinicopathological features and recurrence of differentiated thyroid cancer (DTC), thus analyzing the predictive value of CCL11 and CCL18 levels for recurrence. Methods: One hundred and fifty-one patients with DTC in the hospital from March 2020 to March 2023 were enrolled. The baseline date of Serum CCL11 and CCL18 levels were measured. According to whether or not the recurrence at 1 year of surgery, they were classified into the recurrence group (n=35) and the non-recurrence group (n=116). The baseline levels of serum CCL11 and CCL18 were compared among patients with different clinicopathological characteristics. The predictive value of baseline levels of serum CCL11 and CCL18 levels in evaluating postoperative recurrence was analyzed by receiver operating characteristic curve (ROC). Results: The preoperative serum CCL11 and CCL18 levels were significantly higher in the recurrence group than in the non-recurrence group (P<0.05). Baseline levels of serum CCL11 and CCL18 were associated with lymph node metastasis, depth of invasion, and the tumor-node-metastasis (TNM) staging (P<0.05), but were not related to number of lesions, and microcalcification inside the tumor (P>0.05). ROC curve demonstrated that the area under the curve (AUC) of baseline levels of serum CCL11 and CCL18 alone and in combination in predicting postoperative recurrence of DTC was 0.612, 0.725 and 0.892, with sensitivities of 71.43%, 77.14% and 80.00% and specificities of 55.17%, 62.21% and 90.52% respectively. The efficiency of combined prediction was better than that of each indicator alone (P<0.05). Conclusion: The baseline levels of serum CCL11 and CCL18 are closely related to the clinicopathological characteristics and recurrence of patients with DTC. Measuring preoperative serum CCL11 and CCL18 levels can provide a certain predictive value on postoperative recurrence of the patients.

Key words： Differentiated thyroid cancer C-C motif chemokine ligand 11 C-C motif chemokine ligand 18 Clinicopathological characteristics Recurrence Correlation Predictive value

基金资助:陕西省重点研发计划项目,(编号:2022cy-366)

通讯作者: 郑二良

引用本文:

李栋栋, 郑晨, 郑二良. 分化型甲状腺癌术前血清CCL11 CCL18水平与临床病理特征及复发的关系及预测价值研究[J]. 河北医学, 2025, 31(2): 281-286.
LI Dongdong, ZHENG Chen, ZHENG Erliang. Relationship between Baseline Level of Serum CCL11 and CCL18 with Clinicopathological Features and Recurrence of Differentiated Thyroid Carcinoma and Their Predictive Value. HeBei Med, 2025, 31(2): 281-286.

链接本文:

http://www.hbyxzzs.cn/CN/10.3969/j.issn.1006-6233.2025.02.018 或 http://www.hbyxzzs.cn/CN/Y2025/V31/I2/281

[1] Schlumberger M,Leboulleux S.Current practice in patients with differentiated thyroid cancer[J].Nat Rev Endocrinol,2021,17(3):176-188.
[2] Polosukhina D,Singh K,Asim M,et al.CCL11 exacerbates colitis and inflammation-associated colon tumorigenesis[J].Oncogene,2021,40(47):6540-6546.
[3] Zhou M,Yu H,Bai M,et al.IRG1 restrains M2 macrophage polarization and suppresses intrahepatic cholangiocarcinoma progression via the CCL18/STAT3 pathway[J].Cancer Sci,2024,115(3):777-790.
[4] Shibata M,Inaishi T,Ichikawa T,et al.Identifying the tumor-progressive gene expression profile in high-risk papillary thyroid cancer[J].Surg Today,2021,51(10):1703-1712.
[5] Korbecki J,Olbromski M,Dzigiel P.CCL18 in the progression of cancer[J].Int Mol Sci,2020,21(21):7955-7979.
[6] 华医学会内分泌学分会,中华医学会外科学分会内分泌学组,中国抗癌协会头颈肿瘤专业委员会,等.甲状腺结节和分化型甲状腺癌诊治指南[J].中华核医学与分子影像杂志,2013,33(2):96-115.
[7] Nabhan F,Dedhia PH,Ringel MD.Thyroid cancer,recent advances in diagnosis and therapy[J].Int Cancer,2021,149(5):984-992.
[8] 张瑜,马征泽,王曼,等.甲状腺癌组织中TIPE2、LASP1蛋白表达与其临床病理特征及预后的相关性分析[J].实用癌症杂志,2024,39(1):10-13.
[9] 黄冠又,葛学成,甘鸿川,等.CCL18在胶质母细胞瘤中的表达及其对U87MG细胞增殖和迁移的影响[J].天津医药,2023,51(9):915-921.
[10] 臧荣发,顾盼瑾,尤建良.联合检测血清galectin-3、sIL-2R、CCL11表达水平在评估结肠癌患者预后中的价值研究[J].河北医药,2019,41(10):1460-1463,1468.
[11] Huang X,Lai S,Qu F,et al.CCL18 promotes breast cancer progression by exosomal miR-760 activation of ARF6/Src/PI3K/Akt pathway[J].Mol Ther Oncolytics,2022(25):1-15.
[12] 张福明,张祎苒,王萌,等.CCL11、MK对分化型甲状腺癌患者预后的评估价值[J].解放军医学杂志,2023,48(9):1048-1054.
[13] Sun C,Wang P,Gao T,et al.CCL18 knockdown suppresses cell growth and migration in thyroid cancer[J].Healthc Eng,2022(2022):154-155.